期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重组人MUC1-MBP融合蛋白诱导小鼠Th1活化 被引量：4

Recombinant MUC1-MBP fusion protein activates mouse Th1 cells
下载PDF
导出
摘要 目的检测重组MUC1-MBP融合蛋白对小鼠Th1细胞的活化作用。方法通过生物活性法测定MUC1-MBP免疫鼠脾细胞培养上清液中IL-2I、FN和血清中TNF水平;通过免疫组织化学染色法检测CD4+T细胞在肿瘤组织中的浸润。结果MUC1-MBP免疫鼠脾细胞分泌IL-2和IFN及血清TNF水平较对照组明显增高;MUC1-MBP诱导小鼠CD4+T细胞在肿瘤组织中浸润。结论重组人MUC1-MBP融合蛋白可激活小鼠Th1细胞。 Objective To investigate the activity of Thl cells in mice immunized with recombinant MUC1-MBP fusion protein. Methods The levels of IL-2 and IFN secreted by splenocytes and the serum TNF were detected in mice immunized by recombinant MUC1- MBP. Immunohistechemistry technique was used to analyze the infdtrafion of CD4^＋ T cells into cancerous tissue of MUC1-MBP immunized mice. Results The levels of IL-2 and IFN secreted by splenocytes and the serum TNF were higher in MUC1-MBP-immunized mice than those in the groups of negative control. MUC1-MBP induced the infiltration of CD4^＋ T cells into cancerous tissue. Conchtsion The recombinant MUC1-MBP fusion protein can activate Thl cells of mouse.,
作者 张淑芳 台桂香 马吉春 高航
机构地区 吉林大学基础医学院免疫学教研室
出处 《免疫学杂志》 CAS CSCD 北大核心 2007年第4期373-375,共3页 Immunological Journal
基金 教育部留学归国启动基金资助课题(9922G167)
关键词 MUC1-MBP融合蛋白 TH1细胞 细胞因子 MUC1-MBP fusion protein Th cells Cytokine MUC1 Mucins
分类号 R73-36 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Taylor Papadimitriou J,Burchell J,MilesDW,et al.MUC1 and cancer[J].Biochim Biophys Aeta,1999,1455(2/3):301-313.
  • 2Karanikas V,Hwang L A,Pearson J,et al.Antibody and T cell responses of patients with adenocarcinoma immunised with mannan-MUCl fusion protein[J].J CHn Invest,1997,100(11):2 738-2 792.
  • 3Gilewski T,Adluri S,Ragupathi G,et al.Vaccination of high-risk breast cancer patients with mucin-1 keyhole limpet hemocyanin conjugate plus QS-21[J].Clin Cancer Res,2000,6(5):1 693-1 701.
  • 4台桂香,张吉凤,朱迅.重组人MUC1-MBP融合蛋白的抗肿瘤作用[J].中国肿瘤生物治疗杂志,2003,10(3):202-205. 被引量：13
  • 5Arratt Soyes SM,Vlad A,Finn OJ.Immunization of chimpmzees with tumor antigen MUCl muein tandem repeat peptide elicits both helper and cytotoxic T cell responses[J].Clin Cancer Res,1999,5(7):1 918-1 924.

二级参考文献10

  • 1Taylor-Papadimitriou J, Burchell J, Miles DW, et al. MUC1 and cancer [J]. Biochim Bionhvs Acta,1999, 1455: 301-313.
  • 2Samuel J, Budzynski WA, Reddish MA, et al. Immunogenicity and antitumour activity of a liposomal MUC1 peptide based vaccine[J]. Int J Cancer, 1995, 75: 295-302.
  • 3Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocareinoma immunised with mannan MUC1 fusion protein [J]. J Clin Invest, 1997, 100 (11) : 2738-2792.
  • 4Gilewski T, Adluri S, Ragupathi G, et al. Vaeccination of high-risk breast cancer patients with mucin-1 keyhole limpet hemocyanin conjugate plus QS-21 [J]. Clin Cancer Res, 2000, 5: 1693-1701.
  • 5Takahashi T, Makiguehi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestrieted CTL against MUC1 from a multiple myeloma patient [ J]. J Immunol, 1994,153 : 2102-2109.
  • 6Apostolopoulos V, Karanikas V, Haurum JS, et al. Induction of HLA-A2 restricted CTLs to the mucin 1 human breast cancer antigen [J]. J Immunol, 1997, 159: 5211- 5218.
  • 7Wei YQ. Immunotherapy of tumor with vaccines based on xenogeneious homologous molecules [ J]. Anticancer Drugs, 2002, 13( 3 ) : 229-235.
  • 8Melina SM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUClpeptide with seven tandemly repeated tumor specific epitopes elicit distinct immune effector mechanisms in wildetype versusMUCl-transgenic mice with different potential for tumor rejection [J]. J Immunol, 2001, 18: 6555..6563.
  • 9阎洪彦,王立顺.MUC1粘蛋白—肿瘤生物治疗的新靶点[J].国外医学（免疫学分册）,2000,23(2):113-115. 被引量：9
  • 10张吉凤,台桂香,赵雷,朱迅.鼠与人MUC1分子同源性位点的分析[J].免疫学杂志,2003,19(2):83-85. 被引量：6

共引文献12

同被引文献35

  • 1高航,台桂香,马吉春,柳忠辉.小鼠MUC1基因的克隆及其在大肠杆菌DH5α中的表达[J].中国生物制品学杂志,2007,20(2):91-93. 被引量：4
  • 2Sangha R, North S. L BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer [J]. Expert Opin Biol Ther, 2007, 7 (11): 1723-1730.
  • 3Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase Ⅲ immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1[J]. Breast Cancer Res, 2006, 8 (3): R27.
  • 4Wei YQ, Huang MJ, Yang L, et ah Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen [J].Proc Natl Acad Sci USA, 2001, 98 (20): 11545-11550.
  • 5Nokolova Z, Hof A, Baumlin Y, et al. Combined FTY720/ cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model [ J ]. Transplantation, 2001, 72 (1):168-171.
  • 6Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex - unrestricted recognition of tumour - associated mucins by human cytotoxic T cells[J]. Proc Natl Acad Sci USA, 1989, 86 (18): 7159- 7163.
  • 7Heuser C, Ganser M, Hombach A, et al. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells[J]. Br J Cancer, 2003, 89 (6):1130-1139.
  • 8Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer[J]. Expert Opin Biol Ther, 2007, 7(11): 1723-1730.
  • 9Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer [J]. Expert Rev Vaccines, 2004, 3(6): 655-663.
  • 10Loveland BE, White S, Gan H, et al. Mannan-MUCl-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma[J]. Clin Cancer Res, 2006, 12(3): 869-877.

引证文献4

二级引证文献8

免疫学杂志
2007年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部